Search Results

adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic

results . Clin Cancer Res 2005 ; 11 [ suppl 13 ]: 4984 – 4987 . 16. Kato H Ichinose Y Ohta M . A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung . N Engl J Med 2004 ; 350 : 1713 – 1721

results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253

sarcoma: eight-year experience with adjuvant chemotherapy . J Cancer Res Clin Oncol 1983 ; 106 ( suppl ): 55 – 67 . 16. Sutow WW Sullivan MP Fernbach DJ . Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology

rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. Adjuvant Therapy for Stage II Disease The panel discussed the impact of adjuvant chemotherapy on

Neoadjuvant Approach Phase III trials have demonstrated a clear survival benefit with adjuvant chemotherapy. 5 , 7 Multiple studies examined neoadjuvant therapy as an alternative to the traditional adjuvant approach. Neoadjuvant therapy offers patients the

://www.nccn.org . Accessed May 23, 2006 . 4. Kim ES Vokes EE Kies MS . Cetuximab in cancers of the lung and head & neck . Semin Oncol 2004 ; 31 ( suppl 1 ): 61 – 67 . 5. Hryniuk W Levine MN . Analysis of dose intensity for adjuvant chemotherapy

Background Adjuvant chemotherapy (ACT) with 5-fluorouracil (FU) has been the standard of care for stage III or high-risk stage II colon cancer since the 1990s. 1 This treatment is based on a series of randomized clinical trials (RCTs) showing

positive node negative breast cancers <1 cm often do not need adjuvant chemotherapy while those with stage III disease typically do. Unfortunately, most cases of breast cancer fall between these two extremes and require additional genomics and

.2% PLVB vs 31.9% without PLVB) but completed fewer post-op PT appointments (p<0.0001) (Table1). Patients who received neoadjuvant chemotherapy or adjuvant radiation were more likely to have a pre-op PT appointment, while those who received either adjuvant